As the Omicron variant threatens to derail markets (see CD&R’s recently postponed fundraising effort for its Morrison’s takeover), a look at pandemic-era dealmaking seems a timely place to draw inferences for the near future’s Covid-driven uncertainty. Is the current M&A boom Omicron proof? A recent study shows that one form of dealmaking, the take-private, could indeed be immune.
To read the entire story, you must be logged in.
Please log in now or register with us.
